Go Back to Match Results for "trials"
eFT508 in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone
Study Overview
This study will evaluate the safety, tolerability, antitumor activity, and pharmacokinetics (PK) of eFT508 in patients who have initiated anti-PD-1/anti-PD-L1 monotherapy and either developed progressive disease (PD) on therapy or have undergone 12 weeks of anti-PD-1/anti-PD-L1 therapy with no evidence of partial response (PR) or complete response (CR).
Study Description
This Phase 2, open-label study will evaluate the safety, tolerability, antitumor activity, and pharmacokinetics (PK) of eFT508 in subjects who have initiated anti-PD-1/anti-PD-L1 monotherapy and either developed progressive disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 on therapy or have undergone 12 weeks of anti-PD-1/anti-PD-L1 therapy with no evidence of partial response (PR) or complete response (CR).
Additional Information
Participants will not be paid for their participation.
- IRB Number: 1808981825 (EFT508-0010)
- Research Study Identifier: TX9313
- Principal Investigator: Greg Durm, MD
Recruitment Status
OpenContact the research team to learn more about this study.
Fields marked with asterisk (*) are required
